AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
advancing the standards of care in inflammatory bowel diseases (IBD) Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI ® ) versus ustekinumab (STELARA ® ) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers Additional presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study of risankizumab as a therapy for adults with moderately to severely active ulcerative colitis NORTH CHICAGO, Ill. May 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced it is presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, being held May 18-21 in Washington, D.C. , and virtually. "AbbVie is presenting research at DDW that evaluated rapid symptom relief and visible improvement in the GI tract across our portfolio," said Andrew Anisfeld , Ph.D., vi
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie and FutureGen link on inflammatory bowel disease [Yahoo! Finance]Yahoo! Finance
- BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs [Yahoo! Finance]Yahoo! Finance
- Here's How Many Shares Of AbbVie You Would Need To Earn $500 Per Month In Dividends [Yahoo! Finance]Yahoo! Finance
- June 2024 Insight Into Euronext Paris Growth Stocks With High Insider Ownership [Yahoo! Finance]Yahoo! Finance
- AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 6/3/24 - Form 25-NSE
- 5/31/24 - Form SD
- 5/17/24 - Form 25-NSE
- ABBV's page on the SEC website